List of Tables
Table 1. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Fusion Protein Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 18. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 20. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 27. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 28. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 32. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 33. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 42. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 43. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2021–2026)
Table 51. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2027–2032)
Table 52. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2021–2026)
Table 59. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2027–2032)
Table 60. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2021–2026)
Table 61. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2027–2032)
Table 62. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2021–2026)
Table 69. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2027–2032)
Table 70. Regeneron Pharmaceuticals Company Information
Table 71. Regeneron Pharmaceuticals Description and Business Overview
Table 72. Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 74. Regeneron Pharmaceuticals Recent Developments/Updates
Table 75. Samsung Bioepis Company Information
Table 76. Samsung Bioepis Description and Business Overview
Table 77. Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 79. Samsung Bioepis Recent Developments/Updates
Table 80. Biocon Biologics Company Information
Table 81. Biocon Biologics Description and Business Overview
Table 82. Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 84. Biocon Biologics Recent Developments/Updates
Table 85. Chengdu Kanghong Pharmaceutical Company Information
Table 86. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 87. Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 89. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Fusion Protein Anti-VEGF Ophthalmic Drugs Distributors List
Table 93. Fusion Protein Anti-VEGF Ophthalmic Drugs Customers List
Table 94. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Trends
Table 95. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Drivers
Table 96. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Challenges
Table 97. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Product Picture of Fusion Protein Anti-VEGF Ophthalmic Drugs
Figure 2. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Type: 2025 & 2032
Figure 4. Aflibercept Product Picture
Figure 5. Conbercept Product Picture
Figure 6. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Retail Pharmacies
Figure 10. Other
Figure 11. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size (US$ Million), 2021–2032
Figure 13. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), 2021–2032
Figure 14. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose), 2021–2032
Figure 15. Fusion Protein Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 16. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Share by Manufacturers in 2025
Figure 17. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Players: Market Share by Revenue in Fusion Protein Anti-VEGF Ophthalmic Drugs in 2025
Figure 19. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 22. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 23. United States Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 26. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 27. Germany Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2032)
Figure 34. China Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 42. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 53. Global Revenue Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 54. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2021–2032)
Figure 55. Global Sales Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 56. Global Revenue Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 57. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2021–2032)
Figure 58. Fusion Protein Anti-VEGF Ophthalmic Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
